Form 8-K · Current Report · Filed 2026-01-30
Amgen Terminates License and Collaboration Agreement with Kyowa Kirin
On January 30, 2026, Amgen Inc. announced the termination of its License and Collaboration Agreement with Kyowa Kirin Co., Ltd., which was originally entered into on June 1, 2021. The termination will become effective upon receipt of regulatory approval.
- Filer
- Amgen Inc. AMGN · NASDAQ
- Filed
- Accession
- 0001193125-26-030518
- CIK
- 0000318154
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$342.94
Next session
+0.5%
Since filing
+12.3%
Latest close
$385.16
What happened, not what will happen — closing prices around the filing date.
About Amgen Inc.
Amgen Inc. is a leading biotechnology company focused on the discovery, development, manufacturing, and marketing of human therapeutics. Established in 1980 and headquartered in Thousand Oaks, California, Amgen is recognized for pioneering biologic treatments and having a robust pipeline that targets critical areas like oncology, cardiovascular, and nephrology. The company has harnessed advanced technology platforms and deep scientific expertise to deliver innovative medicines such as Neulasta, Enbrel, and Prolia, which are significant players in the health care sector. Amgen serves markets globally, impacting the biotech industry by transforming the ways diseases are treated. Its investment in state-of-the-art manufacturing facilities and research makes it a significant entity in the pharmaceutical landscape, contributing to long-term health care solutions.
Never miss another AMGN filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.